Gilead Sciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Gilead Sciences sits in the top decile of US sponsors by registered trial count (#71 of 15,742 sponsors by registered trial count).

504 total trials 26 currently recruiting 346 completed early-phase tilt top decile by trial count

Gilead Sciences: 504 sponsored US clinical trials, 26 recruiting.

Gilead Sciences sponsors 504 registered US clinical trials on ClinicalTrials.gov, 26 of them currently recruiting, and 346 completed. 164 of these trials are in Phase 3-4 (later-stage) and 317 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV-1-infection, with 20 trials.

Top-decile sponsor footprint

Gilead Sciences ranks in the top decile of sponsors by registered trial count (#71 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 34/100

346 of 445 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

504 total, page 2 of 11

ACTIVE NOT RECRUITING Phase 1

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

NCT05006794
ACTIVE NOT RECRUITING Phase 3

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

NCT04925752
ACTIVE NOT RECRUITING Phase 2

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

NCT04150068
ACTIVE NOT RECRUITING Phase 2

Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

NCT03964727
ACTIVE NOT RECRUITING Phase 3

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

NCT03301506
ACTIVE NOT RECRUITING Phase 2

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

NCT02881320
ACTIVE NOT RECRUITING Phase 3

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

NCT02842086
ACTIVE NOT RECRUITING Phase 2

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

NCT02016924
ACTIVE NOT RECRUITING Phase 3

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection

NCT01651403
TERMINATED Phase 1

Study of GS-1219 in Participants With HIV-1

NCT07115368
TERMINATED Phase 2

Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

NCT06784973
TERMINATED Phase 2

Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

NCT06585150
TERMINATED Phase 2

Study of Obeldesivir in Children and Adolescents With COVID-19

NCT05996744
COMPLETED Phase 4

Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)

NCT06104306
TERMINATED Phase 2

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT05629208
COMPLETED Phase 1

A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function

NCT05760300
COMPLETED Phase 1

Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function

NCT05765344
COMPLETED Phase 3

Study of Obeldesivir in Nonhospitalized Participants With COVID-19

NCT05715528
COMPLETED Phase 1

Study of Novel Antiretrovirals in Participants With HIV-1

NCT05585307
TERMINATED Phase 1

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

NCT05458102
TERMINATED Phase 2

Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

NCT05330429
TERMINATED Phase 3

Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

NCT05079230
TERMINATED Phase 2

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT04958785
COMPLETED Phase 1

An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

NCT04950764
TERMINATED Phase 2

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

NCT04892446
TERMINATED Phase 2

Study of Magrolimab in Patients With Solid Tumors

NCT04827576
TERMINATED Phase 2

Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

NCT04854499
TERMINATED Phase 1

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT04809623
COMPLETED Phase 2

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT04971785
TERMINATED Phase 3

Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

NCT04778397
TERMINATED Phase 2

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

NCT04778410
COMPLETED Phase 3

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

NCT04620733
COMPLETED Phase 1

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

NCT04811040
TERMINATED Phase 3

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

NCT04745351
TERMINATED Phase 1

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

NCT04747470
COMPLETED Phase 3

Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

NCT04527991
TERMINATED Phase 1

Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

NCT04502706
COMPLETED Phase 1

Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants

NCT04608344
TERMINATED Phase 3

Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting

NCT04501952
COMPLETED Phase 1

Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation

NCT04539262
TERMINATED Phase 3

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

NCT04313881
COMPLETED Phase 4

Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

NCT04319198
COMPLETED Phase 2

Study of Remdesivir in Participants Below 18 Years Old With COVID-19

NCT04431453
COMPLETED Phase 3

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

NCT04292730
COMPLETED Phase 3

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)

NCT04292899
TERMINATED Phase 2

Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis

NCT04130919
TERMINATED Phase 3

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

NCT04115748
COMPLETED Phase 2

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

NCT04143594
TERMINATED Phase 3

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy

NCT04115839
TERMINATED Phase 2

A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC

NCT04024813
← Previous Page 2 of 11 Next →

Phase Distribution

PhaseTrial count
Phase 1 134
Phase 2 183
Phase 3 150
Phase 4 14

Therapeutic Areas

HIV-1-infection 20
HIV Infections 15
Chronic Hepatitis B 8
Hepatitis C 7
HIV 5
Acquired Immunodeficiency Syndrome 4
Triple Negative Breast Cancer 4
Pre-Exposure Prophylaxis of HIV Infection 3
Hepatitis C, Chronic 3
Hepatitis C Virus Infection 3

What is open in the Gilead Sciences pipeline

26 recruiting of 504 indexed (5% open); 346 completed (69%).

Phase mix: 164 late (III/IV) vs 317 early (I/II) (early-phase heavy).

Top condition: HIV-1-infection (20 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Gilead Sciences: open-pipeline peers nationwide

Peers matched on 504 registered trials and 5% open enrollment, not the therapeutic-area sidebar.

Gilead Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600 0%5%10%15%20% Total trials Recruiting share Gilead SciencesH. Lee Moffitt Cancer Center and Research InstituteNational Heart, Lung, and Blood Institute (NHLBI)Boehringer IngelheimNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Creighton UniversityAlmirall, S.A.Cordis USDefense and Veterans Center for Integrative Pain Management
Gilead Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Gilead Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 504 trials (± recruiting share)

Sponsors near 5% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Gilead Sciences page

504 registered trials is a research-attention snapshot, not an endorsement of Gilead Sciences or any single study.

  • 26 of Gilead Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • HIV-1-infection is the condition Gilead Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV-1-infection trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Gilead Sciences pipeline card: 504 registered trials from official public datasets.Report a data error.